Boswellia is sold in two grade families that cannot be dosed interchangeably. Conventional extracts are standardised to 65% total boswellic acids; enriched extracts are standardised to 30% of the single acid AKBA and dosed at a fraction of the weight. Both families have randomised trials behind them, and the meta-analyses pool them. This guide keeps the two apart.
Quick-Reference Dosage Table
| Grade family | Trial dose | What a serving delivers | Duration |
|---|---|---|---|
| AKBA-enriched extract, 30% AKBA | 100 mg/day or 250 mg/day | 30 mg or 75 mg AKBA | 90 days (knee osteoarthritis trial) |
| Conventional extract, 65% total boswellic acids | About 300 to 400 mg two or three times daily (900 to 1,200 mg/day) | 600 to 780 mg total boswellic acids | 8 to 12 weeks |
The pooled evidence: a 2020 meta-analysis of seven randomised trials found Boswellia and its extracts reduced pain and stiffness scores and improved function versus control, and recommended a treatment duration of at least four weeks; a 2024 meta-analysis of thirteen trials found benefit in the placebo-controlled subgroup but high heterogeneity overall; a 2024 sub-group analysis reported larger effects for one standardised extract than for the others. Read together, they support a four-to-twelve-week daily regimen at the dose of the grade you are using, and they warn against assuming all Boswellia extracts behave alike.
Why the Grades Cannot Be Swapped
The 65% figure is a titration or HPLC total of six boswellic acids, of which AKBA is usually 1% to 3% of the extract. An enriched 30% AKBA extract therefore carries ten to thirty times the AKBA of a conventional extract at the same weight, while carrying less of the other acids. A formulator who takes a 250 mg AKBA-enriched trial dose and applies it to a 65% extract delivers a fraction of the studied AKBA; one who applies a 1,000 mg conventional dose to an enriched extract delivers 300 mg of AKBA, far above anything studied. Our boswellic acid assay explainer sets out how each number is measured; the grades article covers the trade-offs.
Onset and Directions
Trials measured outcomes at four, eight and twelve weeks, and the meta-analyses treat four weeks as the minimum duration; improvements continued to twelve weeks in the longer studies. Directions of use should state a daily dose, with food, for at least four weeks. Boswellia extracts are lipophilic and were dosed with meals in most trials; some enriched grades are formulated with a lipid carrier to improve absorption, which is one reason their trial doses are low.
Formulation Notes
- Format. Conventional 65% extracts are pale resinous powders that flow poorly and cap well in size 00 capsules at 400 mg; softgels suit the lipophilic nature of the material. Enriched extracts at 100 to 250 mg fit small capsules or tablets.
- Odour. The characteristic frankincense odour carries into gummies and powders; capsules avoid it.
- Combination products. Boswellia is commonly paired with turmeric; a 2025 network meta-analysis found each effective on different outcomes and called for more data on the combination, so keep each at its own trial dose rather than reducing both.
Safety
Adverse events in the trials were mild and mainly gastrointestinal, with no significant difference from placebo in the pooled analyses. Boswellia is avoided in pregnancy for lack of data. As a gum resin product, it should be specified with a residual solvent test where an organic solvent was used in extraction.
Boswellia Serrata Extract, 65% and AKBA grades
Total boswellic acids and AKBA reported by HPLC on the COA, so the grade matches the dose you formulate.